Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Nov 30;14(11):4715-4718.
doi: 10.21037/tlcr-2025-882. Epub 2025 Nov 27.

T cell receptor (TCR)-based therapy in advanced non-small cell lung cancer: a new hope?

Adrien Costantini  1   2 , Etienne Giroux Leprieur  1   2
Affiliations
Editorial

T cell receptor (TCR)-based therapy in advanced non-small cell lung cancer: a new hope?

Adrien Costantini et al. Transl Lung Cancer Res. .
No abstract available

Keywords: Adoptive cell therapies (ACTs); non-small cell lung cancer (NSCLC); treatment.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2025-882/coif). E.G.L. reports consulting fees from Astra Zeneca, Boehringer-Ingelheim, Bristol-Myers-Squib, Janssen, Lilly, MSD, Pfizer, Roche, Sanofi, and Takeda. The other author has no conflicts of interest to declare.

Comment on

References

    1. Garassino MC, Gadgeel S, Speranza G, et al. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol 2023;41:1992-8. 10.1200/JCO.22.01989 - DOI - PMC - PubMed
    1. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50. J Clin Oncol 2021;39:2339-49. 10.1200/JCO.21.00174 - DOI - PMC - PubMed
    1. Novello S, Kowalski DM, Luft A, et al. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. J Clin Oncol 2023;41:1999-2006. 10.1200/JCO.22.01990 - DOI - PMC - PubMed
    1. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011;29:917-24. 10.1200/JCO.2010.32.2537 - DOI - PMC - PubMed
    1. Ramachandran I, Lowther DE, Dryer-Minnerly R, et al. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. J Immunother Cancer 2019;7:276. 10.1186/s40425-019-0762-2 - DOI - PMC - PubMed